1) Denhardt DT, Noda M, O’Regan AW, Pavlin D, Barman JS. Osteopontin
as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61.
2) Sing K, DeVouge MW, Mukherjee BB,. Physiological properties and
differential glycosylation of phosphorylated and non-phosphorilated froms of osteopontin secreted by normal rat kidney cell. J Biol Chem
1990;265:18696-701
3) Senger DR, Asch BB, Smith BD, Per ruzzi CA, Dvorak HF, A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cell. Nature 1983;302:714-5
4) Smith JH, Denhardt DT. Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cell: induction is stable at high, but not at low, cell densities. J Cell Biochem 1987;34:13-22
5) Oldberg A, Franzen A, Heinegard D. Cloning and sequenze analysis of rat
bone sialoprotein(osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequenze. Proc Natl Acad Sci USA 1986;83:8819-23
6) Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985;232:715-24
7) Patarca R, Freeman GJ, Singh RP, Wei FY, Durfee T, Blattner F, et al.
Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989;170;145-61.
8) Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance of bacterial infection: the role of the early T-lymphocytes
activation-1/osteopontin gene. Crit Rev Immunol 1993;13:225-46
9) Young MF, Kerr JM, Termine JD, et al. cDNA clonino, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990:7;491-502.
10) Franzen A Yokosaki Y, Matsuura N,Sasaki T. The integrin alpha(9)beta(1) binds to a novel recognition sequenze (SVVYGLR) in the trombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999;274:36328-34
11) Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte
12) O’Reagan A, Barman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-90
13) Askar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (Osteopontin): an early component of type 1 (cell-mediated) immunity. Science 2000;287:860-4
14) Nemir M, DeVouge MW, Mukherjee BB. Normal rat kidney cells secrete both phosphorylated and nonphosphorilated forms of osteopontin showing different physiological properties. J Biol Chem 1989;264:18202-8
15) WeberGF, Zawaideh S, Hikita S, et al. Phosphorylation-dependet
interaction osteopontin witj its receptors regulates macrophage migration and activation. J Leukoc Biol 2002;72:752-61.
16) Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.Biochim Biophys
Acta 1996;1314:13-14
17) O’Reagan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Barman JS, Osteopontin is associated with T cells in sarcoid granulomas and has T cell adesive and cytokine-like properties in vitro.J Immunol 1999;
162:1024-31)
18) Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Ancer Res
1985;45:5818-26
19) Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659
20) Agnihotri R, Crawford HC, Haro H, Matrisian LM, Harvda MC, Liaw L.
Osteopontin, a novel substrate for matrix metalloproteinase-3(strmelysin-1) and matrix metalloproteinase-7(matrylisin).J Biol Chem 2001;276:28261-7
21) Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible
structure of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem
Biophys Res Commun 2001;280:460-5
22) Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGS( small integrin-bindin ligand, N-linked glycoproteins)enhance factor H’s cofactor activity enabling-like cellular evasion of complement-mediated attak.J Biol Chem 2002;277:13700-8.
23) Fedarko NS, Forh B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of
complement-mediated attack.J Biol Chem 2000;275:16666-72
24) Hu D, Lin E, Kovach NL, Hoyer JR, Smith JV. A biochimical
characterization of the binding of osteopontin to integrin aVb1 and aVb5. J
Biol Chem 1995;270-26232-8
25) Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, et
al.the adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrino. Role og alpha v beta 3 in smooth muscle cell
migration to osteopontin in vitro. J Clin Invest 1995;95:713-24
26) Denda S, Reichsrdt LF, Muller U.Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell 1998;9:1425-35
27) Barry ST, Ludbrook SB, Murrison E, Horgan CM. A regulated interaction between alpha5beta1 integrin and osteopontin. Biochem Biophys Res
Commun 2000;267:764-9
28) Green PM, Ludbrook SB, Miller DD, Horgan CM, Barry ST. Structural element of osteopontin SVVYGLR motif important for the interaction with alpha(4)integrins. FEEBS Lett 2001;503:75-9
29) Palmer EL, Ruegg C, Fernando R, Pytela R, Sheppard D. Sequence and tissue distribuition of the integrin alpha 9 submit, a novel partner of beta 1 that is widely distributed in epithelia and muscle. J Cell Biol
1993;123:1289-97
30) Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminaldomain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J
Biol Chem 1996;271:28485-91
31) Bayless KJ, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci 1998;111:1165-74
32) Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12
33) Weber GF, Ashkar S, Cantor H. Interaction between cd44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Phys
34) Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with beta1-containing integrino to permit cells to bind to osteopontin indipendently of arginine-glycine-aspartic acid, thereby stimulating cell mobility and chemitaxis. Cancer Res 1999; 59:219-26
35) Denhards DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol
2001;41:723-49
36) Anthony O’ Regan:The role of osteopontin in lung disease. Cytokine and
Growth Factor Reviews 14 (2003) 479-488
37) Tian JY, Sorensen ES, Butler WT, Lopez CA, Sy MS et al. Regulation of NO synthesis induced by inflammatory mediators in RAW 264.7 cells: collagen prevents inhibition by osteopontin. Cytokine 2000;12:450-457
38) Scott JA, Weir ML, Wilson SM, Xuan JW, Chambers AF et al.
Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissues. Am J Physiol 1998;275:H2258- H2265
39) Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G et al.
Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis
Rheum 2001;44:578-584.
40) Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M et al. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lynphoproliferation. Blood
2004;103:1376- 1382
41) Mckee MD, Farach CM, Butler WT, Hanschka PV, Nanci A.
Ultrastructural immunolocalization of noncollagenous (osteopontin and osteocalcin) and plasma (albumin and alpha 2HS glycoprotein) proteins in rat bone. J Bone Miner Res 1993;8:485-496
42) Dodds RA, Connor JR, Jamas IE, Rykaczewski EL, Appelbaum E et al.
Human osteoclasts, not osteoblasts deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. J Bone Miner
Res 1995;10:1666-1680
43) Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin - a possible anchor of osteoclast to bone. Proc Natl Acad Sci
1990;87:4473-4475.
44) Challaiah MA, Kizer N, Biswas R, Alvarez U, Strauss- Schoenberger J et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003;14:173-189
45) Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G.
Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1994; 269:14853-14856
46) Teray K, Takano-Yamamoto T, Ohba Y, Hiura K, Sugimoto M et al. Role of osteopontin in bone remodeling caused by mechanical stress. J Bone
Miner Res 1999;14:839-849.
47) Duncan RL, Turner CH. Mechanotransduction and the functional response of bone to mechanical strain. Calcif Tissue Int 1995;57:344-358
48) Ishijima BM, Rittling SR, Yamashita T, Tsuji K, Kurosawa H et al.
Enhancement of osteoclastic bone resoption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001;193:399-404
49) Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 1999;7:103-113
50) Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomyinduced bone resorption. Proc Natl Acad
Sci 1999;96:8156- 8160
51) Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J,
Tenenbaum HC et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000;18:253-260
52) Withold W, Armbruster FP, Karmatschek M, Reinauer H. Bone sialoprotein in serum of patients with malignant bonediseases. Clinical
Chem 1997;43:85-91
53) Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002;95:506-512
54) Rosol TJ. Pathogenesis of bone metastasis: role of tumorrelated proteins. J
Bone Miner Res 2000;15:844-850
55) Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF et al. NFkB mediates alphav-beta3 integrin-induced endothelial cell survival. J Cell Biol
1998;141:1083 1093
56) Sorensen ES, Rasmussen LK, Moller L, Jensen PH, Hojreys P et al.
Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. Biochem J 1994;304:13-16
57) Kaartinen MT, Pirhonen A, Linnala-Kankkunen A, Maenpaa PH. Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties. J Biol Chem 1999;274:1729-1735
58) Graudal NA, Jurik AG, de Carvlho A, Graudal HK. Radiographic progression in rheumatoid arthritis: a long-term prospectiv study of 109 patientes. Arthritis Rheum 1998, 41:1470-1480
59) Ebheradt KB, Fex E:Functional impairment and disability in early Rheumatoid Arthritis: development over 5 years. J Rheumatol 1995,
22:1037-1042
60) Bazzichi L, Del Debbio A, Vivarelli L, Catena M, Bouanani S, Merlini G, Bombardieri S, Dell’Osso L: Quality of life in rheumatoid arthritis: impact of disability and lifitime depressive spectrum sintomatology. Clin Exp
Rheumatol 2005 Nov-Dec; 23(6): 783-8
61) Harrison TR, Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL. Principi di medicina interna. XIV
ed. Mc Graw-Hill
62) Todesco S, Gambari PF. Malattie reumatiche. Mc Graw-Hill
63) Klippel J, Dieppe PA. Rheumatology. Mosby Doyma Italia
64) Fuchs HA, Pincus T. Evidence of significant radiograficdamage in RA within the first 2 years of disease. J Rheumatology 16:585-591, 1989
65) Dugowson CE, Nelson JL, Koepsell TD, Evaluation of the 1987 revised criteria for rheumatoid arthritis in a cohort of newly diagnosed female patients. Arthritis Rheum. 1990 Jul;33(7):1042-6
66) Ollier W et al. Population genetics of RA. Rheum Dis Clin North Am
1992;18:741-59
67) Mullan HR, Bresnihan B. Disease-modifying anti-rheumatic drug theraphy and structural damage in early rheumatoid arthritis. Clin Exp Rheumatol
2003; 21 (suppl 31): S158-S164.
68) Lovell DJ et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342 (11): 763-9
69) Van Doornum S, McColl G, Wicks IP. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum.2002;46:862-873
70) Lexin W. and Guoqin F.:Rheumatoid arthritis increases the risck of
coronary heart disease via vascular endothelial injuries.Medical Hypoteses,
Vol 63,issue 2, 1004, 442-445
71) Libby P, Ridker PM, MaseriA. Inflammation and atherosclerosis.
Circulation.2002;105:1135-1143
72) Pearson TA, Mensah GA, Alexander RW, et al. Marker of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and The American Hearth Association.
Circulation 2003;107:499-511
73) McInnes IB. Rheumatoid Arthritis: from bench to bedside. Rheum Dis Clin
North Am.2001;27:373-387
74) Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortalità in seventy-five Rheumatoid Arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-872
75) Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and
inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis.
2000;181(suppl 3): S462-S472
76) Lee YH, Choi SJ, Ji JD, et al. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000;19:324-325
77) Munro R, Morrison R, McDonald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with Rheumatoid Arthritis. Ann
Rheum Dis. 1997;56:374-377
78) Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis. 1998; 138:229-235
79) Maziere C, Auclair M, Maziere JC. Tumor necrosis factor enhances low density lipoprotein oxidative modification by monocytes and endothelial cells. FEBS Lett.1994;338:43-46
80) Gambir JK, Lali P, Jain AK. Correaltion between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem.
1997;30:351-355
81) Honkanen V, Kontinnen YT, Mussalo-Rauhamaa H. Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis. Clin Exp
82) Vita JA, Keaney JF Jr. Endothelial function: a barameter for cardiovascular risk. Circulation 2002;106:640-642
83) Hasckard DO. Cell adhesion molecules in rheumatoid arthritis. J
Rheumatol. 1999;26:2044-2048
84) Wong M, Toh H, Wilson A et al. Reduced arterial elasticità in rheumatoid arthritis and the relationship to vascula disease risk factor and inflammation. Arthritis Reum. 2003;48:81-89
85) Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthitis.
Circulation. 2002;106:2184-2187
86) Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endhotelial dysfunction provide a lynk? Lancet.
1997;349:1391-1392
87) Ito A, Tsao PS, Adimoolam S, et al. Novel machanism for endhotelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.
Circulation. 1999;99:3092-3095
88) Sattar N, David W. McCarey, Hilary Capell, Iain B. McInnes:Explaining how ”high grate” systemic inflammatin accelerates vascular risk in reumathoid arthritis: CIRCULATION 2003;108:2957-2963
89) Jurcut C., Jurcut R., Tanasescu C. : Cardiovascular risk and Rheumatoi arthritis: from meccanism of atherosclerosis to therapeutic approach. Rom J
Intern Med. 2004;42/4):659-69
90) Gerli R., Goodson NJ.,: Cardiovascular involvement in rheumatoid arthritis.
Lupus. 2005;14(9):679-82
91) Rincon I., Freeman GL., Haas RW., O’Leary DH., Escalante A.:Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestation to atherosclerosis.Arthritis Rheum:2005 nov;52(11):3413-23.
92) Kamanli A., Naziroglu M., Aydilek N., Hacievliygil C., Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis.
Cell Biochem 2004 Jan-feb;22(1):53-7
93) Karatas F.,Ozates I., CanatanH., Halifeoglu I., Karatepe M.,Colakt R.:Antioxidant status e lipid peroxidation in patients with rheumatoid arthritis.Indian J Med Res 2003 Oct;118:178-81.
94) T.Chard,” An introduction to Radioimmunoassay & Related Techniques 4th Ed.”, (1990) Amsterdam: Elsevier.(P.Tiussen,”Practice & Theory of Enzyme Immunoassays”,(1985) Amsterdam: Elsevier
95) Migdalis IN et al. Plasma level of Endothelin, lipid peroxid and prostacyclin in diabetic patiens with macroangiopathy. Diabetes Res Clin Pract 2001
Nov ;54(2):129-36
96) Wagner et al. Plasma endothelin in patients with acute aortic disease.
Resuscitation 2002 Apr,53(1):71-6
97) Kinugawa T et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure ( in Process Citation ). J Card Fail 2003
Aug;9(4):318-24
98) K.Yagi, in “ Lipidic Peroxides in Biology and Medicine”( K. Yagi, ed.)
p.223. Academic Press, New York, 1982
99) Esterbauer, H., Schaur, R.J. and Zollner, H. (1991) Chemistry and Biochemistry of 4-Hydroxynonenal, Malonaldeyde and Related Aldehydes; Free Rad. Biol.Med. 11, 81-128
